Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial compares the effectiveness of cemiplimab with CDX-1140 to cemiplimab without CDX-1140 prior to surgery in treating patients with stage III-IV head and neck cancer. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. CDX-1140 is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Giving cemiplimab with CDX-1140 versus cemiplimab alone before surgery may make the tumor smaller and may reduce the amount of normal tissue that needs to be removed for patients with stage III-IV head and neck cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjenci z potwierdzonym rakiem płaskonabłonkowym głowy i szyi (w jamie ustnej, gardle, krtani, krtani dolnej, jamie nosowej) w III-IV stopniu zaawansowania, który kwalifikuje się do operacji.
- •Pacjenci mogą mieć nowotwór pierwotny lub nawrotowy.
- •Guz musi być widoczny w badaniach obrazowych lub wyczuwalny podczas badania lekarskiego.
- •Pacjenci powyżej 18. roku życia.
- •Ogólny stan zdrowia pacjenta musi pozwalać na udział w badaniu (grupa 0-2 wg skali ECOG).
✗ Disqualifies
- •Dzieci poniżej 18. roku życia.
- •Pacjenci z rakiem gardła, który jest związany z wirusem HPV (p16-dodatni).
- •Pacjenci, których wątroba lub nerki nie funkcjonują prawidłowo.
- •Pacjenci z innymi poważnymi chorobami współistniejącymi.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 18, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (9)
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, United States
Los Angeles General Medical Center
Los Angeles, United States
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, United States
Emory University Hospital Midtown
Atlanta, United States
Ochsner Medical Center Jefferson
New Orleans, United States
University of Cincinnati Cancer Center-UC Medical Center
Cincinnati, United States
University of Cincinnati Cancer Center-West Chester
West Chester, United States
UPMC Hillman Cancer Center
Pittsburgh, United States
VCU Massey Comprehensive Cancer Center
Richmond, United States
Trial contact
Site Public Contact
Victoria M. Villaflor
PRINCIPAL_INVESTIGATOR
Site Public Contact
Jacob S. Thomas
PRINCIPAL_INVESTIGATOR
Site Public Contact
Jose A. Monteiro de Oliveira Novaes
PRINCIPAL_INVESTIGATOR
Site Public Contact
Daniel Johnson
PRINCIPAL_INVESTIGATOR
Site Public Contact
Chad A. Zender
PRINCIPAL_INVESTIGATOR
Site Public Contact
Kevin J. Contrera
PRINCIPAL_INVESTIGATOR
Site Public Contact
Erin R. Alesi
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.